Curetis to Present at Solebury Trout European Biotech Investor Day in NYC

Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, July 25, 2019, 08:00 am CEST - Curetis N.V. (the "Company" and, together with Curetis USA Inc. and Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that its CEO Oliver Schacht, PhD, will present at the European Biotech Investor Day in New York City, NY, USA, on Thursday, August 1, 2019, at 4pm EST. The life science-focused conference is organized by Solebury Trout and sponsored by Goodwin LLC, Deutsche Bank, H.C. Wainwright and Nasdaq and will be held at offices of Goodwin LLC in the New York Times building.

Oliver Schacht will discuss the progressing commercialization of the Unyvero multiplex PCR platform for molecular microbiology in the U.S., Europe, and Asia and provide an update on partnering activities around the Company´s A30 RQ Platform in development and the recent progress in offering AI-powered, NGS-based molecular microbiology solutions by Curetis’ subsidiary Ares Genetics.

###

About the European Biotech Investor Day

The European Biotech Investor Day in New York City features privately-held and EU-listed biotechnology companies representing the "Next Wave of Opportunities” emerging from Europe. Participating companies offer compelling or novel approaches to addressing a range of indications. To inquire about Solebury Trout or to attend the event, please contact Thomas Hoffman at thoffmann@troutgroup.com.

About Curetis

Curetis N.V.’s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.

Curetis’ Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, thereby facilitating improved patient outcomes, stringent antibiotic stewardship and health-economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.

Curetis’ wholly owned subsidiary Ares Genetics GmbH is developing next-generation solutions for infectious disease diagnostics and therapeutics. The ARES Technology Platform combines the presumably most comprehensive database worldwide on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence.

For further information, please visit www.curetis.com and www.ares-genetics.com.

Legal Disclaimer

This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.

The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.

This press release includes statements that are, or may be deemed to be, "forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes”, "estimates”, "anticipates”, "expects”, "intends”, "may”, "will”, or "should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Contact Details

Curetis GmbH
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com or ir@curetis.com
www.curetis.com

Curetis International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

Solebury Trout Inquiries
SOLEBURY TROUT
Thomas Hoffmann
Managing Director
740 Broadway, 9th Floor
New York, NY 10003
thoffmann@troutgroup.com
soleburytrout.com/lifesciences

Attachment

• 20190725_Curetis_PR_EN_EU_BiotechInvestorDay_final_approved